Literature DB >> 23183784

The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients.

Savas Ozturk1, Serhat Karadag, Metin Yegen, Meltem Gursu, Sami Uzun, Zeki Aydin, Ahmet Gurdal, Macit Koldas, Baki Kumbasar, Rumeyza Kazancioglu.   

Abstract

BACKGROUND: Asymmetric dimethylarginine (ADMA) is accepted as a risk factor for coronary artery disease because it causes endothelial dysfunction and vasospasm. In this study we aimed to investigate the relationship between ADMA levels and echocardiographic and metabolic parameters in peritoneal dialysis (PD) patients.
METHODS: This is a cross-sectional study in which PD patients aged 18-80, with at least 3-month duration of dialysis and without active cardiac, infectious or malignant diseases, and clinically evident hypervolemia, were included. ADMA levels and echocardiographic parameters were recorded.
RESULTS: Of the 55 patients included, the mean age was 53 ± 15 years. Mean ADMA level was 81.9 ± 48.0 μmol/l. The variables found to be positively correlated with ADMA levels were weight, body surface area, body mass index (BMI), serum glucose level, uric acid and sodium levels, ultrafiltration volume, left atrium diameter, intraventricular end-systolic diameter and intraventricular end-diastolic diameter. The parathyroid hormone, dialysate K t/V and ejection fraction were negatively correlated with ADMA levels. ADMA levels were higher in patients with hypertension. With multivariate analysis, gender, BMI and use of acetyl salicylic acid were found to be the independent variables determining ADMA levels.
CONCLUSION: The correlation of ADMA with BMI, gender, hypertension, left atrium diameter, intraventricular end-systolic diameter and intraventricular end-diastolic diameter led to the idea that ADMA may aid in the determination of cardiovascular disease risk in PD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183784     DOI: 10.1007/s10157-012-0739-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  28 in total

1.  K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.

Authors: 
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

2.  Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover.

Authors:  E B Marliss; S Chevalier; R Gougeon; J A Morais; M Lamarche; O A J Adegoke; G Wu
Journal:  Diabetologia       Date:  2005-12-21       Impact factor: 10.122

3.  Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.

Authors:  Emre Avci; Sule Coskun; Erdinc Cakir; Yasemin Kurt; Emin Ozgur Akgul; Cumhur Bilgi
Journal:  Ren Fail       Date:  2008       Impact factor: 2.606

4.  Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.

Authors:  Francesca Mallamaci; Giovanni Tripepi; Sebastiano Cutrupi; Lorenzo S Malatino; Carmine Zoccali
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

5.  Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension.

Authors:  Francesco Perticone; Angela Sciacqua; Raffaele Maio; Maria Perticone; Renke Maas; Rainer H Boger; Giuseppe Tripepi; Giorgio Sesti; Carmine Zoccali
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

6.  Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine.

Authors:  Hilde M A Eid; Harald Arnesen; Elsa M Hjerkinn; Torstein Lyberg; Ingebjørg Seljeflot
Journal:  Metabolism       Date:  2004-12       Impact factor: 8.694

7.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.

Authors:  J T Kielstein; R H Böger; S M Bode-Böger; J Schäffer; M Barbey; K M Koch; J C Frölich
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

8.  Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults.

Authors:  T Janatuinen; R Laaksonen; R Vesalainen; O Raitakari; T Lehtimäki; P Nuutila; J Knuuti
Journal:  J Cardiovasc Pharmacol       Date:  2001-10       Impact factor: 3.105

Review 9.  Novel cardiovascular risk factors in end-stage renal disease.

Authors:  Carmine Zoccali; Francesca Mallamaci; Giovanni Tripepi
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

10.  Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients.

Authors:  Dildar Konukoglu; Hafize Uzun; Sinem Firtina; Pinar Cigdem Arica; Ahmet Kocael; Mustafa Taskin
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.